Analyst Price Target is $8.00
▲ +90.48% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for GeoVax Labs in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 90.48% upside from the last price of $4.20.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in GeoVax Labs.
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever; Zika virus and malari; human immunodeficiency virus (HIV); as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.